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120,458 HUF per life years saved. In the Activated Protein C
treatment arm the average cost–effectiveness was 312,085 HUF
per life years saved (societal viewpoint). CONCLUSION: Incre-
mental efﬁciency of Activated Protein C treatment was compared
to incremental efﬁciency of dialysis and renal transplantation.
Robustness of results was examined through a sensitivity 
analysis.
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OBJECTIVES: To calculate the average cost per patient (case)
and to estimate the cost of primary care of lower respiratory tract
infection (LRTI) in children younger than 3 years of age in
Germany. Costs were evaluated from perspectives of third party
payer, parents and society. METHODS: This economic analysis
was part of the PRI.DE study, a prospective, multicenter, popu-
lation-based epidemiological study carried out over 2 years
(1999–2001) in children with community-acquired LRTI aged 0
to 36 months in Germany. Inclusion of children with pneumo-
nia, bronchitis, bronchiolitis, croup and apnea by 11 ofﬁce-based
pediatricians. Nasopharyngeal secretions were tested for RSV,
parainﬂuenza-(PIV), and inﬂuenza viruses (IV) by Hexaplex PCR
(Prodesse, USA). Drugs and medical services consumed were gen-
erated by chart abstraction. Data regarding parental expenses
was collected via telephone interviews. RESULTS: In 568 out of
1329 cases (43%) total costs could be calculated. On average,
total costs per case were €123 (SD 161€). About 54% was direct
medical cost, 11% direct non-medical cost and 35% indirect
cost. Cost for pneumonia was 205€ (SD 264€); for bronchiolitis
146€ (SD 179€); for bronchitis 101€ (SD 141€) and for croup
82€ (SD 78€). Total cost caused by RSV infections amounted 
to 163€ (SD 172€), caused by parainﬂuenza 100€ (SD 115€),
caused by inﬂuenza 223€ (SD 279€) and caused by other
pathogens 111€ (SD 159€). Based on the annual incidence of
682.128 LRTI cases (children: 0–3 years) and median total cost
(71€), economic burden due to LRTI amount to 48.4€m in
Germany annually. CONCLUSION: Treating LRTI caused by
inﬂuenza and RSV was more expensive than LRTI caused by
parainﬂuenza or other pathogens. Community-acquired LRTI in
children up to the age of 3 years causes a considerable economic
burden to the health care system in Germany.
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OBJECTIVE: Post-operative infections are associated to increase
of mortality and morbidity. The objective of this study was to
estimate the hospital cost of antibiotic therapy in patients under-
going colorectal cancer surgery and the possible inﬂuence of
infections in hospital cost. METHODS: We conducted a natu-
ralistic, longitudinal, retrospective study, considering data from
medical records of all patients undergoing colorectal surgery in
2002 at the Surgical Division of the IRCCS “S. de Bellis” of
Castellana Grotte. RESULTS: Data from 83 patients (mean age
68.6, from 38 to 92 years, 48.2% men) were collected. In order
to prevent infections, when the intervention started, and for 
at least the 48 hours, all patients but one (a patient allergic 
to antibiotics) were treated with 5-nitroimidazole and/or
cephalosporin. If infections occurred, they were treated with one
or more antibiotics: quinolones, carbapenems, amynoglicosides,
cyclosporines and penicillines, according to the type of compli-
cation. Seventeen patients (20.5%) had post-operative infections,
with a higher frequency in older patients (mean age 73.6 vs 67.3,
P = 0.024). Drug therapy cost (expressed as €/hospitalization) to
the hospital was 206.0€ (0.0€–849.2€), for the most part attrib-
utable to prophylactic therapy: a mean of 178.1€ was spent for
prophylaxis, while a mean of 28.5€ were spent for therapy
administered if infection occurred. In patients with infections the
average cost (362.5€) was more than twice than cost for patients
without infections (166.3€). On average drug cost accounted for
3.7% of hospitalisation reimbursements. The average post-
operative length of stay was sensitively longer in patients with
infections (10 vs. 18 days, P < 0.0001). CONCLUSIONS: A ther-
apeutic strategy aimed at preventing chirurgical infections can
accelerate patients’ remission, with repercussion on drug and
hospital cost.
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OBJECTIVES: Depression is a common mental health problem
in HIV+ patients; however, symptoms of depression frequently
go unrecognized. With the development of the Center for Epi-
demiologic Studies—Depression (CESD) scale, it is possible to
identify depression using patient-reported outcomes. This study
evaluates a) the prevalence of depression using patient-reported
vs. physician-diagnosed outcomes & b) whether substitution to
LPV/r affects depression in HIV+ patients. METHODS: PLATO
is an open-label, multi-center, multi-country, Phase IV study.
Patients who were virologically controlled (2 consecutive viral
loads <400c/mL), but experiencing Grade 2 PI/NNRTI-
associated side effects were randomized (4 :1) to immediate sub-
stitution at Baseline or deferred substitution at Week (Wk) 4 of
their PI/NNRTI with LPV/r, while remaining on Baseline NRTI’s.
Patients completed the CESD at Baseline & Wk8. Physician
assessments were performed at Baseline, Wk4 & Wk8. Viral
load, safety, & bothersomeness of HIV & treatment related
symptoms (ACTG Symptoms Distress Module, plus 2 items for
nephrolithiasis) were also followed. RESULTS: In total, 717 of
849 patients (84%) enrolled were not on antidepressant med-
ication at Baseline & completed CESD (79% male, mean age 41
yrs). At Baseline, 295 of 717 patients (41%) self-reported signs
of clinical depression (CESD ≥16) compared to 32 (4.5%) with
physician-diagnosed Grade 1–2 depression (k = 0.059; 95% CI:
0.020–0.097). Prevalence of patient-reported clinical depression
was reduced to 26% (Baseline-Wk8; P < 0.001) following 4–8
Wks of LPV/r, while the prevalence of physician-diagnosed
